AN UPDATE OF A PHASE-II STUDY OF PACLITAXEL IN ADVANCED OR RECURRENT SQUAMOUS-CELL CANCER OF THE CERVIX

Thirty-two evaluable patients with squamous cell cancer of the cervix were treated with i.v. paclitaxel 250 mg/m(2) over 3 h every 21 days. They received standard premedications and granulocyte colony stimulati ng factor (G-CSF) support(5 mu g/kg/day). Median (range) age was 49 (2 9-81) years and performance status Zubrod was 1 (0-2). One patient had a complete response and seven patients had a partial response (25%, 9 5% CI 8-38%). The median survival was 7.3 months. Granulocytopenia was brief and non-cumulative. G-CSF was used for a median (range) of 8 (1 -15) days per cycle. In conclusion: paclitaxel is active in patients w ith squamous cell cancer of the cervix and is well tolerated in this d ose schedule with G-CSF support.